Skip to main content
Upstream Bio, Inc. logo

Upstream Bio, Inc. — Investor Relations & Filings

Ticker · UPB ISIN · US91678A1079 US Manufacturing
Filings indexed 100 across all filing types
Latest filing 2026-05-13 Interim / Quarterly Rep…
Country US United States of America
Listing US UPB

About Upstream Bio, Inc.

https://upstreambio.com/

Upstream Bio, Inc. is a clinical-stage biotechnology company that develops treatments for inflammatory diseases, with a primary focus on severe respiratory disorders. The company's lead product candidate is verekitug, a monoclonal antibody designed to target and inhibit the thymic stromal lymphopoietin (TSLP) receptor, an upstream driver of pro-inflammatory signaling. Verekitug is in clinical development for the treatment of conditions including severe asthma, chronic rhinosinusitis with nasal polyps (CRSwNP), and chronic obstructive pulmonary disease (COPD).

Recent filings

Filing Released Lang Actions
10-Q - Upstream Bio, Inc. (0002022626) (Filer)
Interim / Quarterly Report
2026-05-13 English
8-K - Upstream Bio, Inc. (0002022626) (Filer)
Regulatory Filings
2026-05-13 English
8-K - Upstream Bio, Inc. (0002022626) (Filer)
Regulatory Filings
2026-03-26 English
4 - Upstream Bio, Inc. (0002022626) (Issuer)
Director's Dealing
2026-03-17 English
4 - Upstream Bio, Inc. (0002022626) (Issuer)
Director's Dealing
2026-03-17 English
8-K Filing
Regulatory Filings
2026-02-11 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.